000661.SZ
长春高新
SZSE · Healthcare · C 制造业 · CN
CNY 76.11
−4.26%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
27.8x
Market Cap
CNY 31.05B
MomentumView details →
1D Return
−4.26%
YTD Return
−20.32%
RSI (14)
41.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
27.8x
Market Cap
CNY 31.05B
RSI (14)
41.8
MomentumView details →
1D Return
−4.26%
YTD Return
−20.32%
Similar companies
Latest newsMore news →
Changchun High-tech's subsidiary Jinsai Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of GenSci161 injection, a self-developed biologic drug for connective tissue disease-associated interstitial lung disease.4d agoChangchun High-Tech announced it will not distribute cash dividends, bonus shares, or convert capital reserve to share capital for H1 2026.16d agoChangchun High-Tech announced its H1 2026 results: revenue of 5.543 billion yuan, down 16.06% year-on-year; net profit attributable to shareholders of 475 million yuan, down 51.64% year-on-year; non-GAAP net profit of 496 million yuan, down 52.02% year-on-year.16d ago